TY  - BOOK
AU  - Barac, Ana
TI  - Frequency of Takotsubo Cardiomyopathy in Adult Patients Receiving Chemotherapy (from a 5-Year Nationwide Inpatient Study)
SN  - 0002-9149
PY  - 2019///
KW  - *Antineoplastic Agents/tu [Therapeutic Use]
KW  - *Hospitalization/sn [Statistics & Numerical Data]
KW  - *Neoplasms/dt [Drug Therapy]
KW  - *Takotsubo Cardiomyopathy/ep [Epidemiology]
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Female
KW  - Hospital Mortality
KW  - Humans
KW  - Incidence
KW  - Male
KW  - Middle Aged
KW  - Neoplasms/co [Complications]
KW  - Neoplasms/mo [Mortality]
KW  - Retrospective Studies
KW  - Risk Factors
KW  - United States/ep [Epidemiology]
KW  - Young Adult
KW  - MedStar Heart & Vascular Institute
KW  - Journal Article
N1  - Available online from MWHC library: 1995 - present, Available in print through MWHC library: 1999 - 2006
N2  - Copyright (c) 2018. Published by Elsevier Inc; Takotsubo cardiomyopathy (TC) develops in patients who are under significant emotional, psychosocial, or sudden biochemical stress. However, the added burden of TC on the patients receiving chemotherapy has never been studied. We aimed to describe the additional clinical and economic burden, along with the potential predictors of TC and related in-hospital mortality in patients receiving chemotherapy using the largest inpatient cohort. We identified chemotherapy-related adult hospitalizations using the National Inpatient Sample databases (2010 to 2014). Primary end points were the incidence of TC and the odds of in-hospital mortality. Secondary end points were gender-based incidence differences, length of stay (LOS), hospital charges, and discharge disposition. We identified 1,067,977 chemotherapy-related hospitalizations, of which, 562 hospitalizations revealed TC incidence. Other co-morbidities were also significantly higher in the TC cohort. In unmatched analyses, the LOS (median 17 days vs 5 days) and total hospital charges (median
UR  - https://dx.doi.org/10.1016/j.amjcard.2018.11.006
ER  -